Antibiotics for treating community-acquired pneumonia in people with sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 11, 2016, Pages

  Martí Carvajal, Arturo J ^a   Conterno, Lucieni O ^b  

^a Iberoamerican Cochrane Network   (Venezuela)

^b Marilia Medical School   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SICKLE CELL ANEMIA; SYSTEMATIC REVIEW; ACUTE DISEASE; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; PNEUMONIA, BACTERIAL;

ACUTE DISEASE; ANEMIA, SICKLE CELL; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL;

EID: 84997078058     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005598.pub4     Document Type: Review

References (101)

1. Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. Journal of Pediatrics 2003;143(4):438-44.
2. Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ 1996;313(7054):387-91.
3. Kaushansky K. Special Needs Plan for Chronic Conditions. http://www.hematology.org/policy/testimony/ASH_Comments_re_Special_Needs_Plan_for_Chronic_Conditions.pdf (accessed November 1st 2008).
4. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. American Journal of Epidemiology 2000;151(9):839-45.
5. Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, et al. Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology 2010;85(1):6-13.
6. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
7. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clinical Infectious Disease 2000;31(2):347-82.
8. Battersby AJ, Knox-Macaulay HH, Carrol ED. Susceptibility to invasive bacterial infections in children with sickle cell disease. Pediatric Blood & Cancer 2010;55(3):401-6.
9. Begue P, Castello-Herbreteau B. Severe infections in children with sickle cell disease: clinical aspects and prevention [Infections graves chez renfant ĺ drèpanocytaire aspects cliniques et prèvention]. Archives de Pediatrie 2001;8(Suppl 4):732s-41s.
10. Beytout J, Tournilhac O, Laurichesse H. Asplenia and hyposplenism. La Presse Medicale 2003;32(28 Suppl):S5-9.
11. Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infectious Disease 2004;4(3):144-54.
12. Bonds DR. Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype. Blood Review 2005;19(2):99-110.
13. Castagnola E, Fioredda F. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. European Journal of Haematology 2003;71(5):319-26.
14. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84(2):643-9.
15. Castro O, Gladwin MT. Pulmonary Hypertension in Sickle Cell Disease: Mechanisms, Diagnosis, and Management. Hematology/Oncology Clinics of North America 2005;19(5):881-96.
16. Chalmers I. Well informed uncertainties about the effects of treatments. BMJ 2004;328(7438):475-6.
17. Chanet V, Lesens O, Laurichesse H, Beytout J. Prevention and infection in adults patients with hyposplenism [Infections chez l'adulte asplénique et prévention]. Medecine et maladies infectieuses 2004;34(11):493-8.
18. Davies EG, Hirst C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003885.pub2]
19. De Ceulaer K, McMullen KW, Maude GH, Keatinge R, Serjeant GR. Pneumonia in young children with homozygous sickle cell disease: risk and clinical features. European Journal of Pediatrics 1985;144(3):255-8.
20. Dean D, Neumayr L, Kelly DM, Ballas SK, Kleman K, Robertson S, et al. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. Journal of Pediatric Hematology/Oncology 2003;25(1):46-55.
21. Di Sabatino A, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Corazza GR, et al. Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. The American Journal of Gastroenterology 2005;100(8):1788-95.
22. Falcao RP, Donadi EA. Infection and immunity in sickle cell disease. Revista da Associacao Medica Brasileira 1989;35(2):70-4.
23. File TM. Streptococcus pneumoniae and community-acquired pneumonia: A cause for concern. American Journal of Medicine 2004;117(Suppl 3A):39S-50S.
24. Fleming AF. The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Review 1989;3(1):18-28.
25. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. New England Journal of Medicine 1986;314(25):1593-9.
26. Gilbert DN. Clinical end points of therapy for patients with mild community-acquired pneumonia. Clinical Infectious Diseases 2008;47(Suppl 3):140-4.
27. Golden C, Styles L, Vichinsky E. Acute chest syndrome and sickle cell disease. Current Opinion in Hematology 1998;5(2):89-92.
28. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 09 November 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
29. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
30. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
31. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
32. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
33. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PUBMED: 21802902]
34. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
35. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
36. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380-2. [PUBMED: 21185693]
37. Haas H. Antibiotherapy in children with atypical bacterial infections [Antibiothérapie des infections à bactéries atypiques de l'enfant]. Archives de pediatrie 2005;12(Suppl 1):S45-8.
38. Hampton R, Balasa V, Allen Bracey SE. Emergencies in patients with inherited hemoglobin disorders - An emergency department perspective. Clinical Pediatric Emergency Medicine 2005;6(3):138-48.
39. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004;11:129-51.
40. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
41. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
42. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice. www.ich.org/cache/compo/276-254-1.html (accessed 18th May 2006).
43. Infectious Diseases Society of America. Position Paper: Recommended Design Featuresof Future Clinical Trials of Antibacterial Agents for Community-Acquired Pneumonia. Clinical Infectious Diseases 2008;47(Suppl 3):249-65.
44. Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. American Journal of Medicine 2004;117(Suppl 3A):3S-15S.
45. Jain S, Sullivan K. Ceftriaxone use in the emergency department: are we doing it right?. Pediatric Emergency Care 2002;18:259-64.
46. Kakaiya R, Cseri J, Smith S, Silberman S, Rubinas TC, Hoffstadter A. A case of acute hemolysis after ceftriaxone: immune complex mechanism demonstrated by flow cytometry. Archives of Pathology and Laboratory Medicine 2004;128:905-7.
47. Klugman KP, Low DE, Metlay J, Pechere JC, Weiss K. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. International Journal of Antimicrobial Agents 2004;24(5):411-22.
48. Knight J, Murphy TM, Browning I. The lung in sickle cell disease. Pediatric Pulmonology 1999;28(3):205-16.
49. Landesman SH, Rao SP, Ahonkhai VI. Infections in children with sickle cell anemia. Special reference to pneumococcal and salmonella infections. The American Journal of Pediatric Hematology/Oncology 1982;4(4):407-18.
50. Lane PA, O'Connell JL, Lear JL, Rogers ZR, Woods GM, Hassell KL, et al. Functional asplenia in hemoglobin SC disease. Blood 1995;85(8):2238-44.
51. Lepage P, Dresse MF, Forget P, Schmitz V, Hoyoux C. Infections and antibiotic prophylaxis in sickle cell disease. Revue Medicale de Liege 2004;59(3):145-48.
52. Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology (Am Soc Hematol Educ Program). The American Society of Hematology, 2005.
53. Loureiro MM, Rozenfeld S. Epidemiology of sickle cell disease hospital admissions in Brazil. Revista de Saúde Pública 2005;39(6):943-9.
54. Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. British Journal of Hematology 2005;129(4):449-64.
55. Mâitre B, Mekontso-Dessap A, Habibi A, Bachir D, Parent F, Godeau B, et al. Pulmonary complications in adult sickle cell disease [Complications pulmonaires des syndromes drepanocytaires majeurs chez l'adulte.]. Revue des Maladies Respiratoires 2011;28(2):129-37.
56. Makani J, Williams TN, Marsh K. Sickle cell disease in Africa: burden and research priorities. Annals of tropical medicine and parasitology 2007;101(1):3-14. [PUBMED: 17244405]
57. Makani J, Cox SE, Soka D, Komba AN, Oruo J, Mwamtemi H, et al. Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PloS one 2011;6(2):e14699.
58. Melles DC, de Marie S. Prevention of infections in hyposplenic and asplenic patients: an update. The Netherlands Journal of Medicine 2004;62(2):45-52.
59. Metlay JP. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infectious disease clinics of North America 2004;18(4):777-90.
60. Miller ML, Gao G, Pestina T, Persons D, Tuomanen E. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. Journal of Infectious Disease 2007;195:581-4. [MEDLINE: 17230418]
61. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization 2008;86(6):480-7.
62. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Archives of Internal Medicine 2002;162(9):1059-64.
63. Mousa SA, Qari MH. Diagnosis and management of sickle cell disorders. Methods in Molecular Biology 2010;663:291-307.
64. Neumayr L, Lennette E, Kelly D, Earles A, Embury S, Groncy P, et al. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics 2003;112(1 Pt 1):87-95.
65. National Heart, Lung, and Blood Institute, Division of Blood Disease and Resources. The Management of Sickle Cell Disease. 4th Edition. National Institutes of Health, 2002.
66. Orkin SH, Higgs DR. Medicine. Sickle cell disease at 100 years. Science 2010;329(5989):291-2.
67. Overturf GD. Infections and immunizations of children with sickle cell disease. Advances in Pediatric Infectious Diseases 1999;14:191-218.
68. Overturf GD. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 2000;106(2 Pt 1):367-76.
69. Paradisi F, Corti G. Antibiotic resistance in community-acquired pulmonary pathogens. Seminars in Respiratory and Critical Care Medicine 2000;21(1):33-43.
70. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease. Science 1949;110(2865):543-6.
71. Pelton SI, Hammerschlag MR. Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Clinical Pediatrics 2005;44(1):1-17.
72. Petri, Jr WA. Penicillins, cephalosporins, and other β-lactam antibiotics. In: Hardman JG, Limbird LE editor(s). Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 10. New York: McGraw Hill, 2001:1189-218.
73. Pimentel L, McPherson SJ. Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management. Emergency Medicine Clinics of North America 2003;21(2):395-420.
74. Plouffe Jr JF, Martin DR. Re-evaluation of the therapy of severe pneumonia caused by Streptococcus pneumoniae. Infectious Disease Clinics of North America 2004;18(4):963-74.
75. Prabhakar H, Haywood C Jr, Molokie R. Sickle cell disease in the United States: looking back and forward at 100 years of progress in management and survival. American Journal of Hematology 2010;85(5):346-53.
76. Ramakrishnan M, Moisi JC, Klugman KP, Iglesias JM, Grant LR, Mpoudi-Etame M, et al. Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. The Lancet Infectious Diseases 2010;10(5):329-37.
77. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376(9757):2018-31.
78. The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2011.
79. Sandora TJ, Harper MB. Pneumonia in hospitalized children. Pediatric Clinics of North America 2005;52(4):1059-81.
80. Saunthararajah Y, Vichinsky EP, Embury SH. Sickle cell disease. Hematology: Basic Principles and Practice. Churchill Livingstone, 2005.
81. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. American Journal of Medicine 2005;118(Suppl 7A):21S-8S.
82. Selim AG, Balalis G, Bhaskar B, van Driel ML. Antibiotics for ventilator-associated pneumonia. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD004267.pub3]
83. Serjeant GR. One hundred years of sickle cell disease. British Journal of Haematology 2010;151(5):425-9.
84. Siddiqui AK, Ahmed S. Pulmonary manifestations of sickle cell disease. Postgraduate Medical Journal 2003;79(933):384-90.
85. Steinberg MH. Genetic etiologies for phenotypic diversity in sickle cell anemia. TheScientificWorldJournal 2009;9:46-67. [PUBMED: 19151898]
86. Stuart MJ, Setty BN. Acute chest syndrome of sickle cell disease: new light on an old problem. Current Opinion Hematology 2001;8(2):111-22.
87. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364(9442):1343-60.
88. Tan JS. Nonresponses and treatment failures with conventional empiric regimens in patients with community-acquired pneumonia. Infectious Disease Clinics of North America 2004;18(4):883-97.
89. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997;89(5):1787-92.
90. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. New England Journal of Medicine 2000;342(25):1855-65.
91. Vij R, Machado RF. Pulmonary complications of hemoglobinopathies. Chest 2010;138(4):973-83.
92. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. Journal Clinical of Patholology 2001;54(3):214-8.
93. Waterer GW, Wunderink RG. Genetic susceptibility to pneumonia. Clinics in chest medicine 2005;26(1):29-38.
94. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited Disorders of Hemoglobin. Disease Control Priorities in Developing Countries. Vol. 2nd edition, Washington DC: The World Bank and Oxford University Press, 2006.
95. World Health Organization. Evidence base for the community management of pneumonia. http://www.who.int/child-adolescent-health/New_Publications/CHILD_HEALTH/WHO_FCH_CAH_02.23.pdf (accessed 29 December 2005).
96. WHO 2004. Pneumococcal vaccines. http://www.who.int/vaccines/en/pneumococcus.shtml (accessed 04 February 2005).
97. World Health Organization. Monogenic diseases. http://www.who.int/genomics/public/geneticdiseases/en/index2.html#SCA (accessed 29 December 2005).
98. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radical Biology and Medicine 2008;44(8):1506-28.
99. Zago MA, Bottura C. Splenic function in sickle-cell diseases. Clinical Science (London, England: 1979) 1983;65(3):297-302.
100. Martí-Carvajal AJ, Conterno L. Antibiotics for treating community acquired pneumonia in people with sickle cell disease. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD005598.pub2]
101. Martí-Carvajal AJ, Conterno LO. Antibiotics for treating community acquired pneumonia in people with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD005598.pub3]